Erytech Pharma SA is guided by a strong set of values and a clear corporate philosophy. The company is driven by a commitment to improving patients' lives through innovative therapies. Erytech Pharma SA strives for excellence in research and development, focusing on developing cutting-edge solutions that address unmet medical needs. With a dedication to scientific integrity, Erytech Pharma SA emphasizes collaboration and teamwork to achieve its goals. The company's corporate philosophy is centered around patient-centricity and providing high-quality treatments that enhance patients' well-being. Erytech Pharma SA's values also include transparency, ethical conduct, and sustainability, enabling them to positively impact the healthcare industry.

Erytech Pharma SA is primarily present in the following countries and regions: France, United States, and Europe.

Erytech Pharma SA, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully completed Phase 2b clinical trial for eryaspase, its lead product candidate. Eryaspase demonstrated promising results in patients with metastatic pancreatic cancer. Additionally, Erytech Pharma SA expanded its clinical development program by initiating Phase 3 clinical trials in acute lymphoblastic leukemia and pancreatic cancer. Moreover, the company received Fast Track designation by the FDA for eryaspase in the treatment of pancreatic cancer. These achievements highlight Erytech Pharma SA's dedication to advancing innovative therapies and its potential to make a meaningful impact in the field of oncology.

Erytech Pharma SA is a biopharmaceutical company with a rich history and background. Founded in 2004 and headquartered in Lyon, France, Erytech Pharma specializes in developing innovative therapies based on its proprietary technology, known as ERYCAPS®. The company focuses on developing treatments for severe forms of cancer and rare diseases. Erytech Pharma's unique approach involves encapsulating therapeutic substances within red blood cells to improve their efficacy and safety. They have made significant advancements in the field and have a strong pipeline of potential therapies. With a dedicated team of experts and strategic partnerships, Erytech Pharma continues to make strides in improving patient outcomes.

The main competitors of Erytech Pharma SA in the market include pharmaceutical companies such as Celgene Corporation, Jazz Pharmaceuticals, and Novartis AG. These companies also specialize in biopharmaceuticals and cancer treatment research and development. However, Erytech Pharma SA differentiates itself through its proprietary technology, erythrocyte-based drug delivery platform, which enables targeted cancer therapies. By leveraging its innovative approach, Erytech Pharma SA aims to gain a competitive edge in the market and provide more effective treatments for patients.

Erytech Pharma SA is primarily active in the biotechnology and pharmaceutical industries.

The business model of Erytech Pharma SA revolves around developing and commercializing innovative therapies for rare forms of cancer and orphan diseases. Erytech Pharma SA focuses on utilizing its proprietary technology, ERYCAPS, to encapsulate therapeutic substances within red blood cells. This approach allows for targeted delivery, prolonged circulation, and enhanced efficacy of the drugs. By leveraging their expertise in biotechnology and a deep understanding of patient needs, Erytech Pharma SA aims to improve treatment options and outcomes for patients worldwide.

Pomer Erytech Pharma cena/zisk je -0,51.

Koeficient Erytech Pharma P/S je 8,78.

AlleAktien kvalitatívne skóre pre Erytech Pharma je 1/10.

Tržby spoločnosti očakávaná Erytech Pharma sú 1,07 mil. EUR.

Zisk očakávaná Erytech Pharma je -18,53 mil. EUR.

Erytech Pharma SA is an emerging company dedicated to the development and commercialization of innovative therapies for rare diseases. The company is headquartered in France and operates globally. Erytech Pharma SA utilizes its proprietary technology to provide safe and effective treatment options to its customers, aiming to improve the quality of life for patients. The business model of Erytech Pharma SA is based on three pillars: research and development, production, and distribution of medications. The research and development department of Erytech Pharma SA focuses on discovering new therapies for rare diseases, particularly in the treatment of leukemia and pancreatic cancer. The company has developed several groundbreaking technologies, including the Erytech technology, which allows for the encapsulation of medications in red blood cells to prolong their effect and reduce the toxicity of the medication. The company also collaborates closely with leading scientists and research institutions to explore new treatment possibilities and further develop its technologies. The product range of Erytech Pharma SA currently includes two medications: eryaspase and erymethionase. Eryaspase is an enzyme derived from the bacteria Erwinia chrysanthemi and is used for the treatment of leukemia. Eryaspase is packaged in red blood cells and slows down the breakdown of chemotherapy drugs in the body, reducing toxicity and increasing effectiveness. Erymethionase is another enzyme used for the treatment of hereditary homocystinuria syndrome. This enzyme is also packaged in red blood cells and aims to normalize methionine metabolism in the body. Erytech Pharma SA has its own production facility, enabling the company to manufacture its medications in-house. The production facility is certified to the highest quality standards and meets the requirements of the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Additionally, the company has a network of distributors and partners that market its products worldwide. To optimize its business model, Erytech Pharma SA has developed a clear expansion strategy. The company strengthens its pipeline through the development of new medications and the expansion of its product portfolio. At the same time, the company works closely with regulatory authorities to ensure fast approval of its products. Furthermore, the company aims to target its product marketing by expanding its customer base and exploring new distribution channels. In summary, Erytech Pharma SA is an emerging company dedicated to the development and commercialization of innovative therapies for rare diseases. The company has a strong research and development department, enabling the development of groundbreaking technologies and the discovery of new medications. Erytech Pharma SA has a broad product range, currently including eryaspase and erymethionase. The company has its own production facility and a strong distribution network. The company is well-positioned to continue growing and strengthen its position in the market for rare diseases in the coming years.

Erytech Pharma vypláca dividendu vo výške 0 EUR rozdelenú do výplat počas roka.

Dividenda pre Erytech Pharma sa aktuálne nedá vypočítať alebo spoločnosť nevypláca dividendu.

ISIN spoločnosti Erytech Pharma je FR0011471135.

WKN spoločnosti Erytech Pharma je A1T94R.

Ticker spoločnosti Erytech Pharma je PHXM.PA.

V posledných 12 mesiacoch spoločnosť Erytech Pharma vyplatila dividendu vo výške . To zodpovedá dividendovému výnosu približne . Pre nadchádzajúcich 12 mesiacov bude pravdepodobne spoločnosť Erytech Pharma vyplácať dividendu 0 EUR.

Súčasný výnos z dividend spoločnosti Erytech Pharma je .

Erytech Pharma vypláca dividendu každý štvrťrok. Tá je vyplácaná v mesiacoch .

Erytech Pharma platil každý rok počas posledných 0 rokov dividendu.

Na nasledujúcich 12 mesiacov sa očakávajú dividendy vo výške 0 EUR. To zodpovedá dividendovému výnosu 0 %.

Erytech Pharma je priradený sektoru 'Zdravie'.

Aby ste obdržali poslednú dividendu vo výške 0 EUR od Erytech Pharma z dňa 9. 8. 2024, museli ste mať akciu v depozite pred ex-dňom 9. 8. 2024.

Posledná dividenda bola vyplatená 9. 8. 2024.

V roku 2023 boli od Erytech Pharma 0 EUR vyplatené ako dividendy.

Dividendy spoločnosti Erytech Pharma sú vyplácané v EUR.